All-oral interferon-free treatments: The end of hepatitis C virus story, the dream and the reality

Table 1 Direct-acting antiviral agents approved for the treatment of hepatitis C virus in interferon-sparing regimens

DAAs	Class	Generation	Activity
Simeprevir	NS3-4A	Second-wave, first generation	Genotypes 1 and 4
Paritaprevir	NS3-4A	Second-wave, first generation	Genotypes 1 and 4
Sofosbuvir	Nucleoside/nucleotide	Nucleotide analogue	Pangenotype
	analogues
Dasabuvir	Non-nucleoside inhibitors of the HCV RNA-dependent	Palm domain I inhibitor	Genotype 1
	RNA polymerase
Daclatasvir	NS5A inhibitors	First-generation	Pangenotype
Ledipasvir	NS5A inhibitors	First-generation	Genotypes 1, 3, 4, 5, and 6
Ombitasvir	NS5A inhibitors	First-generation	Genotypes 1 and 4

DAAs: Direct-acting antiviral agents; HCV: Hepatitis C virus.